8 results
Showing 1–8 · 0.17 seconds · RSS
Cancer Treatment Reviews
Scopus
ISSN 0305-7372 · Elsevier BV · 8 articles in the index
-
Journal Article
Global challenges and policy solutions in breast cancer control
Breast cancer is the leading cause of cancer morbidity, disability and mortality in women, worldwide. Overall, in 2020, it was the most diagnosed malignancy. Differences in breast cancer mortality have been historically evidenced, as a result of disparities in access to diagnosis, treatment and…
-
Journal Article
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Strategies for unlocking immunosuppression in the tumor microenvironment have been investigated to overcome resistance to first-generation immune checkpoint blockade with anti- programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte associated…
-
Journal Article Full text
MYC as a target for cancer treatment
The MYC gene which consists of 3 paralogs, C-MYC, N-MYC and L-MYC, is one of the most frequently deregulated driver genes in human cancer. Because of its high prevalence of deregulation and its causal role in cancer formation, maintenance and progression, targeting MYC is theoretically an…
-
Journal Article
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that drive GC oncogenesis. Further, tumor…
-
Journal Article
Biomarkers for immunotherapy response in head and neck cancer
Preclinical data suggest that head and neck squamous cell carcinoma (HNSCC) is a profoundly immunosuppressive disease, characterized by abnormal secretion of proinflammatory cytokines and dysfunction of immune effector cells. Based on landmark phase III trials, two anti-Programmed Cell Death-1…
-
Journal Article
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking the beginning for a new line of anti-cancer treatments, bevacizumab remains the…
-
Journal Article
Review of precision cancer medicine: Evolution of the treatment paradigm
In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of…
-
Journal Article Full text
How did lomustine become standard of care in recurrent glioblastoma?
Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are more often affected. First-line management includes maximum safe surgical resection followed by involved-field radiotherapy plus concomitant and six cycles of maintenance…